Bourla: Pfizer AI shift cut resistance, sped trials

Pfizer's AI push did not start in a lab — it started in a cost program. After COVID revenue fell off a cliff, the company launched an enterprise-wide cost realignment in October 2023 and later added extra net savings targets, mostly in selling, informational and administrative costs, credited in large part to digital enablement, automation and AI. So AI's measurable job at Pfizer sits on the cost side: shrinking selling and administrative spend so R&D can grow without crushing margins.

Underneath the culture story is a structural swap. On Pfizer's adjusted operating lines, SI&A falls from 2025 actual to the 2026 guidance midpoint while adjusted R&D rises, and the selling-and-admin cut covers roughly 81% of the planned R&D increase, with Pfizer guiding to stable operating margins. The reorganization also came with a smaller top team holding bigger jobs and discipline-based "clans" meant to spread lessons across departments — coordination overhead booked in calendars rather than headcount.

Bourla has been careful not to declare victory, telling the paper he isn't certain this is the right way to do it, only that he has made choices he hopes are right. The evidence for the reorg remains his own account: lower resistance is a feeling, not a metric, and there is no published adoption rate, cycle-time number, or before-and-after. Pfizer's disclosure notice attached to its August call also adds a specific line that anticipated savings from AI, automation and digital enablement may not arrive in the expected amounts or on schedule.